Technology Milestone Details

BharatRohan announced it has achieved a significant internal technology milestone in applying its proprietary hyperspectral imaging platform to pharmaceutical quality screening. In controlled proof-of-concept testing, the Company's imaging system demonstrated the ability to non-destructively differentiate genuine pharmaceutical tablets from adulterated or substandard samples by capturing and analyzing spectral signatures across the visible and near-infrared portions of the spectrum.

Testing Methodology and Results

The Company conducted internal proof-of-concept testing across multiple drug categories:

  • Tested a widely used analgesic-antipyretic tablet from a common adulterant on a pixel-by-pixel basis
  • Extended testing to broader panel including analgesic, macrolide antibiotic, anti-diabetic tablets, and fixed-dose combinations (anti-allergy/anti-asthma combinations and penicillin plus beta-lactamase-inhibitor antibiotic combination)
  • Examined dosage variation, underdosing and adulteration with common pharmaceutical excipients
  • Genuine material and adulterants were mixed by weight at genuine-to-adulterant ratios of 100:0, 90:10, 70:30, 50:50 and 0:100 (pure adulterant)
  • Adulterants tested included calcium carbonate (chalk), starch, talc, microcrystalline cellulose, gypsum and lactose
  • In fixed-dose combination tablets adulterated at 30% by weight with talc, corn starch or chalk, each adulterant produced a distinct spectral signature
  • In a second fixed-dose combination, loss of spectral feature associated with active ingredient indicated possible dilution
  • Antibiotic tablet testing showed coated, uncoated and generic formulations could be distinguished by spectral response
  • Analgesic tablets from different manufacturers showed highly similar spectral profiles at active-ingredient level
  • Early testing indicates spectral signal shifts proportionally to degree of adulteration, suggesting potential for semi-quantitative estimation

Limitations and Next Steps

Results are based on controlled internal testing using limited sample set and have not been independently validated, peer-reviewed, or assessed by any regulatory or pharmacopoeial authority. Company is continuing to expand testing to assess effects of tablet coatings and packaging and cover wider range of formulations.

Regulatory Engagement

Company is engaged in discussions with multiple regulatory and scientific authorities in India's pharmaceutical quality ecosystem to explore pathways for validating and potentially piloting this technology. The specific nature, status, or content of these discussions are not disclosed. No assurance that engagements will result in formal pilot, validation, sample-testing arrangement, or commercial relationship.

Global Operations

BharatRohan operates research and development subsidiary GroeiGids B.V. in the Netherlands, established in October 2024, which focuses on advancing hyperspectral imaging technology and applications. The subsidiary provides a base for engaging with European pharmaceutical and agri-technology stakeholders.

Intellectual Property and Collaboration

Company welcomes dialogue with pharmaceutical manufacturers, contract testing laboratories, distributors and technology partners interested in exploring pilot evaluations, subject to appropriate confidentiality and collaboration agreements.

Market Opportunity Assessment

Company provided preliminary internal estimates of market potential (unaudited, not independently verified, subject to revision):

  • Total Addressable Market (TAM): ~US$0.8-1.8 billion (annual-equivalent basis)
  • Serviceable Addressable Market (SAM): ~US$80-350 million (annual-equivalent basis)
  • Serviceable Obtainable Market (SOM): ~US$1.5-8 million (cumulative over 3 years)

These estimates consider potential use by pharmaceutical manufacturers, marketing authorization holders, contract manufacturing organizations, testing laboratories and regulators. Estimates based on internal assumptions about market structure, adoption rates, and deployment economics with system costs spread over assumed five-year life.

Company Background

BharatRohan Airborne Innovations Limited is an India-based advanced technology company specializing in hyperspectral imaging and AI-powered analytics with established commercial applications in drone-based precision agriculture and food supply chain. The Company is expanding technology applications across pharmaceuticals, solar energy, asset monitoring, infrastructure, freight route simulation, commercial plantations, and other sectors.

Through GroeiGids B.V., the Company also owns BharatRohan INC., a Delaware-incorporated subsidiary focused on building a technology-enabled, farm-to-jar spice and ingredient platform for the U.S. market.

Forward-Looking Statements Disclaimer

The press release contains forward-looking statements subject to risks and uncertainties including outcome of regulatory discussions, technology validation, market acceptance, competitive developments, and other factors beyond Company's control. Actual results may differ materially.

Financial Impact

Financial impact not quantified in the disclosure. Commercial opportunity contingent on successful technical and regulatory validation, pharmacopoeial or regulatory acceptance, and commercial adoption.